Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma MarPHMMF 79 EV-to-EBIT is 19.65 as of Jul. 24, 2026, which is 112% above its 10-year median of 9.25. GuruFocus rates PHMMF with a GF Score™ of 79/100 and a GF Value™ of $91.09 (Fairly Valued). The stock has 3 warning signs investors should review. Among 376 Biotechnology companies, Pharma Mar ranks worse than 61.17% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pharma Mar's Enterprise Value for the quarter that ended in Mar. 2026 was $1,522.3 Mil.
Pharma Mar's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $72.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Mar EV-to-EBIT Related Terms
Pharma Mar EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Pharma Mar's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharma Mar's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pharma Mar's EV-to-EBIT falls into.
Pharma Mar's current Enterprise Value is $1,422.4 Mil.
Pharma Mar's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $72.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Mar (PHMMF) has a EV-to-EBIT of 19.65 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pharma Mar and its competitors. This is 112% above median its historical median of 9.25. According to the industry distribution chart, Pharma Mar ranks #230 out of 376 companies in the Biotechnology industry, placing it in the top 61.2%.
Is Pharma Mar's EV-to-EBIT too high?
Pharma Mar's current EV-to-EBIT of 19.65 is 112% above median its 10-year median of 9.25. The Biotechnology industry median EV-to-EBIT is 12.95. Pharma Mar's value of 19.65 is 51.8% above this industry median. Based on the distribution chart, Pharma Mar ranks #230 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharma Mar has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #230 out of 376 companies for EV-to-EBIT. This places Pharma Mar in the lower half of its industry. The industry median EV-to-EBIT is 12.95. Pharma Mar's value of 19.65 is 51.8% above this benchmark. While the company's 10-year median is 9.25 vs. the industry median of 12.95, Pharma Mar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.95, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Mar's current EV-to-EBIT of 19.65 is 51.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pharma Mar and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Mar's current EV-to-EBIT is 19.65, which is 112% above median its own 10-year median of 9.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Fairly Valued. The stock's GF Value™ is $91.09, compared to a current price of $86.09 — trading 5.5% below its estimated fair value. The current EV-to-EBIT is 19.65, which is 112% above median its 10-year median of 9.25 and 51.8% above the Biotechnology industry median of 12.95. Pharma Mar's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current EV-to-EBIT is 19.65 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (PHMMF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of $86.09 is trading 5.5% below its estimated GF Value™ of $91.09.
GuruFocus considers Pharma Mar to be Fairly Valued.
Key valuation signals for PHMMF:
EV-to-EBIT: 19.65 (112% above median its 10-year median of 9.25)
GF Value™: $91.09 vs. price of $86.09 (5.5% below fair value)
Industry Position: 51.8% above the Biotechnology median (#230 of 376)
No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
79GF Score
Get the complete analysis for PHMMF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHMMF has been successfully added to your 
